Responsum for CKD

{{user.displayName ? user.displayName : user.userName}}
{{ user.userType }}
Welcome to

Responsum for CKD

Already a member?

Sign in   
Do you or someone you know have CKD?

Become part of the foremost online community!

Sign Up Now

Or, download the Responsum for CKD app on your phone

Science Daily

Science Daily

Can MRAs reduce the need for dialysis?

Can MRAs reduce the need for dialysis?

Learn more about MRAs, a commonly prescribed medication in CKD, and their effectiveness in delaying dialysis.


Published on {{articlecontent.article.datePublished | formatDate:"MM/dd/yyyy":"UTC"}}
Last reviewed on {{articlecontent.article.lastReviewedDate | formatDate:"MM/dd/yyyy":"UTC"}}

How much do you know about the medications you take to help prevent the progression of chronic kidney disease (CKD)? Based on your bloodwork and health conditions, your doctor chooses the best medications to help treat CKD and delay its progression. One group of medications commonly prescribed is mineralocorticoid receptor antagonists (MRAs). These drugs work by suppressing the action of aldosterone, a steroid hormone that increases the retention of salt and water in the body.

MRAs have long been associated with improved kidney function in CKD patients through the reduction of blood pressure, swelling, and urine protein levels, but scientists at Osaka University discovered a research gap on the drugs’ effectiveness in reducing the need for dialysis. Learn more about what they did, what they found, and what it means.

What they did

Using data from 3,100 individuals with CKD, researchers conducted a retrospective study to analyze the association between MRA use and the initiation of dialysis. They included various populations of CKD patients, including those with diabetes, heart disease, and/or severely impaired renal function. 

What they found

The research team found that taking MRAs was associated with a 28% lower rate of dialysis initiation and a 24% lower rate of the combined outcomes of dialysis initiation and death. 

What it means

These results show a strong association between the use of MRAs and improved real-world outcomes in CKD patients with different health backgrounds, and support the use of MRAs in treatment plans for diverse groups of people with CKD who are not yet on dialysis.

*Osaka University. (2022, March 23). Improving prognosis in chronic kidney disease. ScienceDaily. Retrieved March 29, 2022 from www.sciencedaily.com/releases/2022/03/220323093641.htm

Source: {{articlecontent.article.sourceName}}

 

Join the CKD Community

Receive daily updated expert-reviewed article summaries. Everything you need to know from discoveries, treatments, and living tips!

Already a Responsum member?

Available for Apple iOS and Android